Editing Disseminated intravascular coagulation (section)

==Treatment==
Treatment of DIC is centered on treating the underlying condition. Transfusions of [[platelets]] or [[fresh frozen plasma]] can be considered in cases of significant bleeding, or those with a planned invasive procedure. The target goal of such transfusion depends on the clinical situation. [[Cryoprecipitate]] can be considered in those with a low [[fibrinogen]] level. Treatment of thrombosis with anticoagulants such as heparin is rarely used due to the risk of bleeding.{{citation needed|date=July 2020}}

Recombinant human activated [[protein C]] was previously recommended in those with severe sepsis and DIC, but [[drotrecogin alfa]] has been shown to confer no benefit and was withdrawn from the market in 2011.<ref>{{Cite web|last=Armstrong|first=Drew|date=October 25, 2011|title=Lilly Pulls Xigris Off Markets After Sepsis Drug Fails Study|url=https://www.bloomberg.com/news/articles/2011-10-25/lilly-pulls-xigris-from-markets-after-sepsis-drug-fails-study|access-date=June 26, 2020|website=[[Bloomberg News]]}}</ref>

Recombinant factor VII has been proposed as a "last resort" in those with severe hemorrhage due to obstetric or other causes, but conclusions about its use are still insufficient.<ref name="Franchini">{{cite journal|last=Franchini|first=M |author2=Manzato, F |author3=Salvagno GL|s2cid=37247533 |title=Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review|journal=Blood Coagul Fibrinolysis|year=2007|volume=18|issue=7|pages=589–93|pmid=17890943|doi=10.1097/MBC.0b013e32822d2a3c|display-authors=etal}}</ref>